Gilead Sciences, Inc. $GILD Shares Purchased by Groupe la Francaise

Key Points

• Groupe la Francaise increased its Gilead Sciences stake by 30.9% in the second quarter, purchasing 11,712 additional shares and bringing its holdings to 49,627 shares valued at approximately $6.27 million. Institutional investors collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year and above analyst expectations, while adjusted earnings of negative $6.75 per share beat estimates. The company declared a quarterly dividend of $0.82 per share, representing a 2.2% yield.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $158.04, despite several recent target-price reductions. Gilead shares opened at $150.99, near their one-year high of $157.29.

Groupe la Francaise raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,627 shares of the biopharmaceutical company's stock after purchasing an additional 11,712 shares during the period. Groupe la Francaise's holdings in Gilead Sciences were worth $6,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Persistent Asset Partners Ltd acquired a new stake in Gilead Sciences in the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the 4th quarter worth approximately $25,000. Kimelman & Baird LLC purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 85 shares during the last quarter. Finally, Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $26,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $150.99 on Tuesday. The firm's fifty day moving average is $137.17 and its two-hundred day moving average is $136.36. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market cap of $187.22 billion, a PE ratio of -56.55 and a beta of 0.33. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. During the same period last year, the firm earned $2.01 EPS. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's dividend payout ratio is currently -122.85%.

Analyst Ratings Changes

GILD has been the subject of a number of analyst reports. Daiwa Securities Group lowered their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a research note on Tuesday, May 19th. Truist Financial cut their price target on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. Leerink Partners downgraded Gilead Sciences from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Rothschild & Co Redburn decreased their target price on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Finally, Morgan Stanley lowered their price target on Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating for the company in a report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $158.04.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company's stock, valued at $1,459,771.32. This trade represents a 33.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 15,000 shares of the firm's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer directly owned 592,133 shares of the company's stock, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 105,000 shares of company stock worth $14,495,820. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.